The MCCC considers the developmental funds as one of the most critical components of CCSG support. Together with institutionally derived Cancer Center discretionary funds and the annual grant support from the Fraternal Order of Eagles, these funds provide seed monies necessary to either initiate research projects or generate pilot data for subsequent grant applications. It should not be surprising, given the small size of the developmental fund pool ($175,000/yr) relative to the substantial expansion realized over the last funding period, that Mayoprovided discretionary funds have contributed more than 90% of the monies needed for seed or pilot projects, for program or shared resource initiation, and all funds for instrumentation and new laboratory set-up costs. Funding is requested in the next project period to support initiatives in the following categories: new cores; equipment; recruitment; and pilot projects. The Cancer Center's review and planning process is rigorous. Investigator-initiated and programmatic proposals must demonstrate a clear probable trajectory for sustained peer reviewed funding, and proposals for enhancement of our shared resources must be for quality services or technologies that address a critical current or projected need - they must add value. The Center has also recognized the importance of these funds in support of high risk projects that might otherwise not be accorded funding through traditional peer review. These projects are particularly encouraged by the MCCC. Nonetheless, they must meet the same scientific standards as other proposals as a prerequisite for funding consideration.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-32
Application #
7253312
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
32
Fiscal Year
2006
Total Cost
$365,505
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications